Share on StockTwits

Dr. Reddy's Laboratories Limited (NYSE:RDY) hit a new 52-week high on Tuesday , AnalystRatings.NET reports. The stock traded as high as $48.22 and last traded at $48.12, with a volume of 163,556 shares trading hands. The stock had previously closed at $47.21.

RDY has been the subject of a number of recent research reports. Analysts at Zacks reiterated an “outperform” rating on shares of Dr. Reddy's Laboratories Limited in a research note on Tuesday, August 5th. They now have a $54.00 price target on the stock. Analysts at TheStreet upgraded shares of Dr. Reddy's Laboratories Limited from a “hold” rating to a “buy” rating in a research note on Thursday, July 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $54.00.

The stock’s 50-day moving average is $44.95 and its 200-day moving average is $43.49. The company has a market cap of $8.198 billion and a price-to-earnings ratio of 20.88.

Dr. Reddy's Laboratories Limited (NYSE:RDY) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.54 earnings per share for the quarter. The company had revenue of $486.00 million for the quarter, compared to the consensus estimate of $474.00 million.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an integrated global pharmaceutical company.

Receive News & Ratings for Dr Reddy's Laboratories Limited (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr Reddy's Laboratories Limited (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.